New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes
Journal Title:
American Society of Clinical Oncology Educational Book
Original Publication Date:
Jun 2025
Bone Marrow Disease(s):
Background: Hematopoietic cell transplantation (HCT) remains the only curative therapy for pediatric myelodysplastic syndrome (MDS) in all but rare cases. While HCT outcomes for pediatric MDS are similar across the largest registry and single-center trials, factors identified as contributing to inferior outcomes vary from study to study. We performed an analysis to provide more clarity on the prognostic implications of disease characteristics, including blast burden and cytogenetic abnormalities, in the current era.